Clicky

Ionis Pharmaceuticals Inc(ISI) News

Date Title
Oct 9 Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
Oct 8 New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
Jul 25 Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
Jul 23 Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
Jul 23 Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug
Jun 19 Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Jun 18 Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Jan 23 Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
Jan 22 UPDATE 2-Ionis Pharma's genetic disease drug succeeds in late-stage study
Jan 22 Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Jan 22 Ionis says rare disease drug succeeds in late-stage HAE study
Jan 19 Insider Sell: EVP CLO & General Counsel Patrick O'Neil Sells 7,744 Shares of Ionis ...
Dec 30 EVP CLO & General Counsel Patrick O'Neil Sells 20,825 Shares of Ionis Pharmaceuticals Inc
Dec 24 Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares
Dec 21 WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dec 21 CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug
Dec 20 12 Most Promising Gene Editing Stocks According to Hedge Funds
Dec 20 Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
Dec 19 Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
Dec 18 Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema